ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

secukinumab

Also written as “Secukinumab”, “AIN457” and “Secukinumab 300 mg”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylitis, Ankylosing · Arthritis, Rheumatoid · Hidradenitis Suppurativa, led by 3 companies.

Drug pageSecukinumab: every studyAll 177 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 12, 2015128 company-led studies, 4 open or runningNext primary completion: Feb 8, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis1254 open or runningphase 4since Jul 12, 2015Dec 21, 2007Feb 8, 2028phase 4 · NCT05622708
Taizhou Mabtech Pharmaceuticalits history only20 open or runningphase 1since Jan 29, 2023Jan 29, 2023none ahead
Johnson & Johnsonits history only10 open or runningphase 1since Oct 13, 2020Oct 13, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Feb 25, 2015.

  1. Nov 4, 20202 phase 3 studiesNCT04632927, NCT04737330
  2. Jan 14, 20212 phase 3 studiesNCT04711902, NCT04732117
  3. Jun 15, 2021Phase 3 study in Giant Cell ArteritisNCT04930094 · 354 enrolled · United States, Argentina, Australia and more
  4. Jan 12, 20222 phase 3 studiesNCT05206591, NCT05232864
  5. Feb 22, 2022Phase 3 study in Giant Cell ArteritisNCT05380453 · 151 enrolled · Germany
  6. Oct 4, 2022Phase 3 study in TendinopathyNCT05569174 · 62 enrolled · Germany
  7. Nov 9, 2022Phase 4 study in Non-Radiographic Axial SpondyloarthritisNCT05622708 · 240 enrolled · Belgium, Brazil, Colombia and more
  8. Jan 27, 2023Phase 3 study in Rotator Cuff TendinopathyNCT05722522 · 33 enrolled · United States, Argentina, Bulgaria and more
  9. Feb 1, 2023Phase 3 study in Rotator Cuff TendinopathyNCT05758415 · 60 enrolled · United States, China, Italy and more
  10. Mar 6, 2023Phase 3 study in Polymyalgia RheumaticaNCT05767034 · 381 enrolled · United States, Argentina, Australia and more
  11. Nov 8, 2023Phase 1 study in Giant Cell ArteritisNCT06130540 · 65 enrolled · United States, Czechia, Italy and more
  12. Mar 20, 2024Phase 3 study in Polymyalgia RheumaticaNCT06331312 · 162 enrolled · United States, Argentina, Australia and more
  13. Dec 20, 2024Phase 1 study in Arthritis, JuvenileNCT06751238 · 20 planned · United States
  14. Mar 18, 2026Phase 4 study in Hidradenitis SuppurativaNCT07489573 · 36 planned · China

Ahead

  1. Feb 8, 2028Primary completion: phase 4 study in Non-Radiographic Axial SpondyloarthritisNCT05622708
  2. May 8, 2028Primary completion: phase 3 study in Polymyalgia RheumaticaNCT06331312
  3. Sep 25, 2029Primary completion: phase 4 study in Hidradenitis SuppurativaNCT07489573
  4. Oct 31, 2029Primary completion: phase 1 study in Arthritis, JuvenileNCT06751238

TargetBeta

IL17A →read by rule
“A recombinant human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), ”NCIt, by rule
“Interleukin 17A inhibitor”ChEMBL 37, by rule

Other programs on IL17A

ProgramCompanyFurthest phaseStudies
ixekizumabruleEli Lillyphase 438
vunakizumabruleJiangsu HengRui Medicinephase 417
bimekizumabruleUCBphase 343
sonelokimabrulemoonlake-immunotherapeutics-agphase 312
simepdekinraEli Lillyphase 27
tibulizumabruleEli Lillyphase 25
SCT650CruleSinocelltech Groupphase 23
UA026ruleusynova-pharmaceuticals-ltdphase 11

Studies

The newest 60 of 125 Novartis leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07489573Hidradenitis Suppurativa · China4RecruitingSep 25, 202936
NCT06751238Arthritis, Juvenile · United States1RecruitingOct 31, 202920
NCT06331312Polymyalgia Rheumatica · United States, Argentina, Australia and more3Active, not recruitingMay 8, 2028162
NCT06130540Giant Cell Arteritis · United States, Czechia, Italy and more1CompletedMar 12, 202565
NCT05767034Polymyalgia Rheumatica · United States, Argentina, Australia and more3CompletedSep 10, 2025381
NCT05758415Rotator Cuff Tendinopathy · United States, China, Italy and more3TerminatedOct 17, 202460
NCT05722522Rotator Cuff Tendinopathy · United States, Argentina, Bulgaria and more3TerminatedOct 17, 202433
NCT05622708Non-Radiographic Axial Spondyloarthritis · Belgium, Brazil, Colombia and more4Active, not recruitingFeb 8, 2028240
NCT05569174Tendinopathy · Germany3CompletedDec 18, 202462
NCT05380453Giant Cell Arteritis · Germany3CompletedFeb 24, 2026151
NCT05232864Lupus Nephritis · Australia, Brazil, Colombia and more3TerminatedAug 23, 202331
NCT05206591Active Peripheral Spondyloarthritis (pSpA)3WithdrawnMar 20, 20280
NCT04930094Giant Cell Arteritis · United States, Argentina, Australia and more3CompletedApr 11, 2025354
NCT04732117Non-Radiographic Axial Spondyloarthritis · China3CompletedApr 3, 2024137
NCT04711902Arthritis, Psoriatic · China3CompletedJun 2, 202241
NCT04737330Graves Ophthalmopathy · Germany3TerminatedMay 16, 202328
NCT04632927Arthritis, Psoriatic · Germany3CompletedOct 22, 2024119
NCT04488185Psoriasis4WithdrawnMar 24, 20210
NCT04237116Non-alcoholic Fatty Liver Disease · Germany, Spain3TerminatedJun 29, 202110
NCT04300296Lichen Planus · United States, France, Germany2CompletedNov 16, 2021111
NCT04181762Lupus Nephritis · United States, Argentina, Australia and more3TerminatedSep 13, 2023275
NCT04179175Hidradenitis Suppurativa · United States, Argentina, Australia and more3CompletedMay 26, 2023702
NCT04209205Arthritis, Psoriatic · United States, Brazil, Bulgaria and more3CompletedMay 17, 2022381
NCT04156620Spondylitis, Ankylosing · United States, Belgium, Brazil and more3CompletedFeb 17, 2022527
NCT03765788Giant Cell Arteritis · Germany2CompletedJun 8, 202152
NCT03769168Arthritis, Juvenile · United States, Belgium, Germany and more3CompletedNov 7, 202455
NCT03713632Hidradenitis Suppurativa · United States, Argentina, Belgium and more3CompletedSep 23, 2021545
NCT03713619Hidradenitis Suppurativa · United States, Argentina, Australia and more3CompletedOct 1, 2021544
NCT03668613Skin Diseases · United States, Belgium, Czechia and more3CompletedSep 19, 201984
NCT03589885Plaque Psoriasis · United States, Canada, Germany and more3CompletedNov 19, 2019122
NCT03504852Psoriasis · United States, Canada, Czechia and more3CompletedSep 13, 2019331
NCT03344640Tendinopathy · United States, Czechia, Germany and more2CompletedAug 2, 201996
NCT03350815Spondylitis, Ankylosing · United States4CompletedMar 11, 2021322
NCT03259074Spondylitis, Ankylosing · United States, Argentina, Australia and more3CompletedNov 12, 2021859
NCT03136861Spondylarthritis · Belgium, Bulgaria, Croatia and more3CompletedFeb 15, 2019383
NCT03066609Skin Diseases · China, Hungary, Malaysia and more3CompletedDec 21, 2017543
NCT03055494Psoriasis · United States4CompletedApr 25, 2018102
NCT03031782Arthritis, Juvenile · United States, Belgium, Germany and more3CompletedOct 7, 202086
NCT03020199Psoriasis · Argentina, Bulgaria, Canada and more4CompletedNov 30, 2021196
NCT02798211Arthritis, Psoriatic · United States, Puerto Rico4CompletedDec 5, 2018258
NCT02896127Spondylitis, Ankylosing · China, Czechia, Korea, Republic of and more3CompletedMay 14, 2018458
NCT02763046Spondylitis, Ankylosing · Germany4CompletedSep 24, 2019211
NCT02750592Spondylitis, Ankylosing · Japan3CompletedJul 5, 201730
NCT02745080Arthritis, Psoriatic · United States, Australia, Bulgaria and more3CompletedDec 30, 2019853
NCT02771210Arthritis, Psoriatic · Bulgaria, Czechia, Germany and more3CompletedDec 11, 2019204
NCT02721966Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more3CompletedJun 26, 2019503
NCT02748863Psoriasis · United States, Belgium, Canada and more3CompletedAug 8, 2017214
NCT02690701Psoriasis · United States4CompletedApr 26, 201791
NCT02752776Plaque, Amyloid · Belgium, Bulgaria, Czechia and more4CompletedMar 28, 20181,660
NCT02662985Arthritis, Psoriatic · United States, Argentina, Austria and more3CompletedNov 10, 2020166
NCT02826603Plaque Psoriasis · United States, Canada, Czechia and more3CompletedJul 9, 20181,114
NCT02607774Moderate to Severe Plaque Psoriasis · United States1CompletedDec 20, 201625
NCT02696031Axial Spondyloarthritis · United States, Australia, Austria and more3CompletedJul 1, 2019555
NCT02559622Psoriasis · Germany3CompletedApr 2016151
NCT02547714Plaque Psoriasis · Japan4CompletedMay 2, 201634
NCT02471144Chronic Severe Plaque-type Psoriasis · United States, Belgium, Colombia and more3CompletedDec 13, 2018162
NCT02474082Psoriasis · Germany3CompletedJun 2016202
NCT02409667Plaque, Amyloid · Austria, Belgium, Bulgaria and more3CompletedMar 14, 201716,487
NCT02474069Skin Diseases · Germany3CompletedSep 15, 2016772
NCT02595970Psoriasis · France3CompletedFeb 9, 2017120

How it is read

Names in the registry

  • “Secukinumab”, 47 entries
  • “AIN457”, 38 entries
  • “secukinumab”, 7 entries
  • “Secukinumab 300 mg”, 6 entries
  • “Secukinumab (AIN457)”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.